Prediction of the Impact Of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2019 Jun 15

PMID 31199498

Citations 11

Authors

Felix Huth

Anne Gardin

Kenichi Umehara

Handan He

Affiliations

Soon will be listed here.

Abstract

We predicted the drug-drug interaction (DDI) potential of siponimod in presence of cytochrome P450 (CYP)2C9/CYP3A4 inhibitors/inducers in subjects with different CYP2C9 genotypes by physiologically-based pharmacokinetic (PK) modeling. The model was established using in vitro and clinical PK data and verified by adequately predicting siponimod PK when coadministered with rifampin. With strong and moderate CYP3A4 inhibitors, an increased DDI risk for siponimod was predicted for CYP2C9*3/*3 genotype vs. other genotypes area under the curve ratio (AUCR): 3.03-4.20 vs. ≤ 1.49 for strong; 2.42 vs. 1.14-1.30 for moderate. AUCRs increased with moderate (2.13-2.49) and weak (1.12-1.42) CYP3A4/CYP2C9 inhibitors to the same extent for all genotypes. With strong CYP3A4/moderate CYP2C9 inducers and moderate CYP3A4 inducers, predicted AUCRs were 0.21-0.32 and 0.35-0.71, respectively. This complementary analysis to the clinical PK-DDI studies confirmed the relevant influence of CYP2C9 polymorphism on the DDI behavior of siponimod and represented the basis for the DDI labeling recommendations.

Citing Articles

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.

Baker D, Forte E, Pryce G, Kang A, James L, Giovannoni G Mult Scler Relat Disord. 2022; 69:104425.

PMID: 36470168 PMC: 9678390. DOI: 10.1016/j.msard.2022.104425.

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations.

Jeong H, Kim M, Wei Z, Lee K, Lee J, Song I Pharmaceutics. 2022; 14(6).

PMID: 35745870 PMC: 9230797. DOI: 10.3390/pharmaceutics14061298.

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.

Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M Patient Prefer Adherence. 2022; 16:1307-1319.

PMID: 35637684 PMC: 9148218. DOI: 10.2147/PPA.S221882.

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials.

Chaoyang C, Xiu D, Ran W, Lingyun M, Simiao Z, Ruoming L Front Pharmacol. 2022; 13:824232.

PMID: 35620290 PMC: 9127076. DOI: 10.3389/fphar.2022.824232.

Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.

Lin W, Chen Y, Unadkat J, Zhang X, Wu D, Heimbach T Pharm Res. 2022; 39(8):1701-1731.

PMID: 35552967 DOI: 10.1007/s11095-022-03274-2.

References

Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018; 391(10127):1263-1273. DOI: 10.1016/S0140-6736(18)30475-6. View

Fahmi O, Maurer T, Kish M, Cardenas E, Boldt S, Nettleton D . A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos. 2008; 36(8):1698-708. DOI: 10.1124/dmd.107.018663. View

Vormfelde S, Brockmoller J, Bauer S, Herchenhein P, Kuon J, Meineke I . Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther. 2009; 86(1):54-61. DOI: 10.1038/clpt.2009.40. View

Caudle K, Rettie A, Whirl-Carrillo M, Smith L, Mintzer S, Lee M . Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014; 96(5):542-8. PMC: 4206662. DOI: 10.1038/clpt.2014.159. View

Scott S, Khasawneh R, Peter I, Kornreich R, Desnick R . Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010; 11(6):781-91. PMC: 2904527. DOI: 10.2217/pgs.10.49. View

Van Booven D, Marsh S, Mcleod H, Whirl Carrillo M, Sangkuhl K, Klein T . Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010; 20(4):277-81. PMC: 3201766. DOI: 10.1097/FPC.0b013e3283349e84. View

Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S . Metabolism and Disposition of Siponimod, a Novel Selective S1P/S1P Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. Drug Metab Dispos. 2018; 46(7):1001-1013. DOI: 10.1124/dmd.117.079574. View

Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C . The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012; 167(5):1035-47. PMC: 3485666. DOI: 10.1111/j.1476-5381.2012.02061.x. View

Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G . In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. Eur J Clin Pharmacol. 2017; 74(4):455-464. PMC: 5849655. DOI: 10.1007/s00228-017-2404-2. View

10.

Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z . Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects. Clin Pharmacokinet. 2018; 58(3):349-361. PMC: 6373376. DOI: 10.1007/s40262-018-0700-3. View

11.

Gardin A, Shakeri-Nejad K, Feller A, Huth F, Neelakantham S, Dumitras S . Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. Eur J Clin Pharmacol. 2019; 75(11):1565-1574. DOI: 10.1007/s00228-019-02729-7. View

12.

Kim K, Johnson J, Derendorf H . Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004; 44(10):1083-105. DOI: 10.1177/0091270004268128. View

13.

Gardin A, Gray C, Neelakantham S, Huth F, Davidson A, Dumitras S . Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. Eur J Clin Pharmacol. 2018; 74(12):1593-1604. DOI: 10.1007/s00228-018-2533-2. View

14.

Fahmi O, Kish M, Boldt S, Obach R . Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos. 2010; 38(9):1605-11. DOI: 10.1124/dmd.110.033126. View

15.

Kirchheiner J, Brockmoller J . Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005; 77(1):1-16. DOI: 10.1016/j.clpt.2004.08.009. View

16.

Neal J, Kunze K, Levy R, OReilly R, Trager W . Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos. 2003; 31(8):1043-8. DOI: 10.1124/dmd.31.8.1043. View